Bruker's ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval's MassInsight™ High-Throughput Pha

Before you go, we thought you'd like these...
Before you go close icon

Bruker's ultrafleXtremeMALDI-TOF/TOF to be Coupled with Nextval's MassInsightHigh-Throughput Pharmaceutical Assay Platform

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker today announces a collaboration between Bruker and Nextval for high-throughput screening of drugs and their metabolites using Bruker's ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval's MassInsight technology.

ultrafleXtreme MALDI-TOF/TOF system (Photo: Business Wire)

ultrafleXtreme MALDI-TOF/TOF system (Photo: Business Wire)

The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam IITM laser with its Perpetual Ion Source for unrivalled productivity, ensuring optimum performance for low concentration high-throughput screening. The versatility of Bruker's CompassTM software allows integration with Nextval's screening technology to maximize sample density and reduce sample analysis costs.


Nextval's MassInsight screening technology is based on novel surface chemistries coupled with unique microarray acoustic deposition methods (EDC Biosystems & BioSero LLC) that address critical needs in several industries including the pharmaceutical, testing and industrial markets.

Dr. Matthew Greving, CSO of Nextval, stated: "The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity." Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialize their MassInsight technology for high-throughput enzyme assays.

Dr. Paul Speir, Senior Vice President of Bruker Daltonics stated: "We are excited by the combination of Nextval's MassInsight technology with the information rich, high throughput capabilities provided by the ultrafleXtreme. Moreover, we are pleased to support Nextval in their efforts to develop this important technology for the rapid and economical screening of drug candidates."

About Bruker Corporation

Bruker Corporation (NAS: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information, please visit www.bruker.com.

Follow Us On:

About Nextval Corporation

Nextval, Inc. is a company developing next generation high-throughput high-content mass based screening assays. For more information please visit www.nextval.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50439924〈=en



Bruker Corporation
Vicky Lander, +1-978-663-3660
Director of Global Marketing Communications Services
vicky.lander@bdal.com
or
Nextval Corporation
Matthew Greving, 858-863-6398
Chief Scientific Officer
matt.greving@nextval.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article Bruker's ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval's MassInsight™ High-Throughput Pharmaceutical Assay Platform originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners